Inovio has two flu vaccines at late stages of the product pipeline. Their VGX-3400 and its universal influenza vaccine have also shown positive results during development and trial stages. However, other companies like AVI BioPharma (AVII) and Antigenics (AGEN) might win the race for the first swine flu vaccine

CelSci’s preclinical studies on its Ligand Epitope Antigen Presentation System (LEAPS) have demonstrated that vaccines using this system have the potential to induce protection against the swine flu. Companies like GlazoSmithKline (GSK), AstraZeneca (AZN) and AVI Biopharma (AVII) are also developing alternatives for the swine flu vaccine and cures for the H1N1 virus.

With advanced orders from the UK government for over 60 million doses of its swine flu vaccine, GlaxoSmithKline UK is preparing to sell £3bn worth of swine flu drugs this year. Glaxo is Britain’s biggest pharmaceutical supplier and has deals with world governments for its antiviral treatment Relenza, which can relieve swine flu symptoms. Is that good enough to consider this company as an investment option?